Last reviewed · How we verify
Quadrivalent seasonal influenza vaccine GSK2282512A
Quadrivalent seasonal influenza vaccine GSK2282512A is a influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of seasonal influenza disease caused by four different influenza viruses. Also known as: GSK2282512A.
This vaccine stimulates the body's immune system to produce antibodies against four different influenza viruses.
This vaccine stimulates the body's immune system to produce antibodies against four different influenza viruses. Used for Prevention of seasonal influenza disease caused by four different influenza viruses.
At a glance
| Generic name | Quadrivalent seasonal influenza vaccine GSK2282512A |
|---|---|
| Also known as | GSK2282512A |
| Sponsor | GlaxoSmithKline |
| Drug class | influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The quadrivalent seasonal influenza vaccine GSK2282512A contains inactivated viruses that cannot cause infection but can still trigger an immune response. This immune response helps the body to recognize and fight off future infections by producing antibodies that can bind to the surface proteins of the influenza viruses.
Approved indications
- Prevention of seasonal influenza disease caused by four different influenza viruses
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
- Muscle pain
- Fever
Key clinical trials
- Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children (PHASE3)
- Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age (PHASE3)
- A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent seasonal influenza vaccine GSK2282512A CI brief — competitive landscape report
- Quadrivalent seasonal influenza vaccine GSK2282512A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Quadrivalent seasonal influenza vaccine GSK2282512A
What is Quadrivalent seasonal influenza vaccine GSK2282512A?
How does Quadrivalent seasonal influenza vaccine GSK2282512A work?
What is Quadrivalent seasonal influenza vaccine GSK2282512A used for?
Who makes Quadrivalent seasonal influenza vaccine GSK2282512A?
Is Quadrivalent seasonal influenza vaccine GSK2282512A also known as anything else?
What drug class is Quadrivalent seasonal influenza vaccine GSK2282512A in?
What development phase is Quadrivalent seasonal influenza vaccine GSK2282512A in?
What are the side effects of Quadrivalent seasonal influenza vaccine GSK2282512A?
Related
- Drug class: All influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of seasonal influenza disease caused by four different influenza viruses
- Also known as: GSK2282512A